Alto Neuroscience (ANRO) stock: insider trades, news & valuation
Net sellingShare price and insider trades
Alto Neuroscience insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 1 sold $3.6M of ANRO stock on the open market.
Get emailed when insiders cluster-buy stocks like ANRO
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
ANRO insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $3.6M | 3 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 Alto Neuroscience, Inc. insiders reported open-market purchases totaling $0, while 1 insider reported sales totaling $3.6M. 3 of 3 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
ANRO earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Aug 12, 2026 | +3.3% | None | +12.2%S&P +0.9% | -0.9% |
| Jul 13, 2026 | +4.7% | None | +5.0%S&P -0.4% | +16.2% |
| May 13, 2026 | +1.5% | None | -4.2%S&P +1.4% | -9.0% |
| Mar 16, 2026 | +15.4% | None | +0.4%S&P +1.3% | +16.5% |
| Nov 12, 2025 | +9.4% | None | -15.3%S&P -1.6% | +33.3% |
| Aug 13, 2025 | +2.9% | None | -1.9%S&P +0.4% | +24.7% |
| May 14, 2025 | -1.7% | None | +2.5%S&P +0.6% | -0.8% |
| Mar 20, 2025 | -10.0% | None | -5.4%S&P -0.3% | -14.7% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 1SEC | Nicholas Conrad SmithCFO, President | Sell Plan | 110,83024,060 held (−82%) | $26.58 | $2.9M | -8.3% | — |
| Oct 1SEC | Nicholas Conrad SmithCFO, President | Sell Plan | 23,17024,946 held (−48%) | $25.78 | $597K | -5.5% | — |
| Oct 1SEC | Nicholas Conrad SmithCFO, President | Sell Plan | 88624,060 held (−4%) | $26.87 | $24K | -9.3% | — |
Insiders at Alto Neuroscience, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Nicholas Conrad SmithCFO, President | — | $3.6M | Oct 1, 2026 | — |
ANRO stock: common questions
Are Alto Neuroscience, Inc. insiders buying ANRO stock?
In the past 12 months, 0 insiders reported open-market purchases of ANRO worth $0.
Are Alto Neuroscience, Inc. insiders selling ANRO stock?
1 insiders reported sales worth $3.6M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ANRO's 52-week range?
Over the past year ANRO has traded between $5.62 and $36.64. It last closed at $24.37 on Oct 9, 2026.